Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 1;139(5):583-585.
doi: 10.1001/jamaophthalmol.2021.0349.

MOG-IgG Among Participants in the Pediatric Optic Neuritis Prospective Outcomes Study

John J Chen  1   2   3   4 , Stacy L Pineles  5 , Michael X Repka  6 , Sean J Pittock  2 , Robert J Henderson  7 , Grant T Liu  8 ; Pediatric Eye Disease Investigator Group (PEDIG)
Affiliations

MOG-IgG Among Participants in the Pediatric Optic Neuritis Prospective Outcomes Study

John J Chen et al. JAMA Ophthalmol. .

Abstract

This study examines the association of myelin oligodendrocyte glycoprotein immunoglobulin G–associated disorder with pediatric optic neuritis to guide prognosis and treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Pittock reports grants from Grifols and the Autoimmune Encephalitis Alliance; honoraria and travel expenses from MedImmune, Inc and Alexion Pharmaceuticals, Inc; consulting fees from Astellas; personal fees from Genentech Sage Therapeutics, and Prime Therapeutics, UCB, Inc, and Hoffman/LaRoche AG; and consulting compensation from Euroimmun outside the submitted work; and has patents 8,889,102 for neuromyelitis optica autoantibodies as a marker for neoplasia and 9,891,219B2 for methods for treating neuromyelitis optica by administration of eculizumab to an individual that is aquaporin-4-IgG autoantibody positive; and pending patents for GFAP-IgG, Septin-5-IgG, MAP1B-IgG, Kelch-like protein 11, and PDE10A. No other disclosures were reported.

Comment in

  • Optic neuritis and MOGAD.
    Htet ZM, Tallantyre E. Htet ZM, et al. J Neurol. 2023 Jun;270(6):3278-3279. doi: 10.1007/s00415-023-11738-7. Epub 2023 May 8. J Neurol. 2023. PMID: 37154890 No abstract available.

References

    1. Chen JJ, Flanagan EP, Jitprapaikulsan J, et al. . Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol. 2018;195:8-15. doi:10.1016/j.ajo.2018.07.020 - DOI - PMC - PubMed
    1. Jurynczyk M, Messina S, Woodhall MR, et al. . Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140(12):3128-3138. doi:10.1093/brain/awx276 - DOI - PubMed
    1. Hacohen Y, Banwell B. Treatment approaches for MOG-Ab-associated demyelination in children. Curr Treat Options Neurol. 2019;21(1):2. doi:10.1007/s11940-019-0541-x - DOI - PMC - PubMed
    1. Writing Committee for the Pediatric Eye Disease Investigator Group . Assessment of pediatric optic neuritis visual acuity outcomes at 6 months. JAMA Ophthalmol. 2020;138(12):1253-1261. doi:10.1001/jamaophthalmol.2020.4231 - DOI - PMC - PubMed
    1. Song H, Zhou H, Yang M, et al. . Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China. Br J Ophthalmol. 2019;103(6):831-836. doi:10.1136/bjophthalmol-2018-312399 - DOI - PubMed

Publication types